Stoney! We need a Gummy of the Day. Hey btw, did you notice that commercial didn't run at all yesterday?
There is a sad humor to my life. Nothing can go completely well. Went to get my second shot with my wife. No judgements I'll just tell you exactly what happened. Went in to an auditorium, went behind a curtain got my shot, my wife got hers we then came out and sat in the chairs for 15 minutes and the next person went in behind the curtain.No problem. Suddenly the curtain is thrown back and the nurse who helped us looks a bit panicked.. she looks around wildly and pushed the guy she was working on down to a different nurse and then Summons help by waving to the back of the room. I wonder what's wrong. Two important looking people rush past and they all go behind the curtain and then they emerge (with worried looks ) carrying a carton of the vaccine which if I was to guess was not cold enough or had an open top and was tampered with or spoiled or... and they all disappeared leaving me and my wife to think what did we just get put into our bloodstream out of that same box. Morning everyone. Van what does btfd mean? - Biden Totally Fucked Democrats?
It's so funny you said that YES I DID NOTICE IT WAS NOT ON! Big time. It was as if the Aliens have left.... I am not up to my usual 100% alertness...) ) ) But here we go your gummy of he day-- SWIM IPO Swimming Pool maker Latham Group prices IPO at $19 per share Latham Group(NASDAQ:SWIM)has priced its initial public offering of20M shares at $19 per share, at lower range of the estimated price of $19-$21. Underwriters' over-allotment is an additional 3M shares. Trading commences today on Nasdaq and the offering is expected to close on April 27. Latham intends to use the proceeds to repay some of its indebtedness under certain credit facilities, including its term and revolving credit facility indebtedness, to acquire shares of common stock from its principal stockholders and a current employee. Park Hotels & Resorts closes W New Orleans–French Quarter sale; provides March operating metrics Park Hotels & Resorts(NYSE:PK) closedon the sale of the 97-room W New Orleans – French Quarter for gross proceeds of ~$24.1M. Post adjustment for Park's forecasted capex, the sale price represents a 4.3% capitalization rate on the hotel's 2019 net operating income or 17.9x of 2019 EBITDA. Sale proceeds will be used for debt repayment. The sale marks the 25th non-core hotel that Park has sold or disposed of since its spin-off from Hilton in January 2017; gross proceeds from these 25 hotels total over $1.2B. Recently, the company reopened three West Coast hotels due to improving demand trends in their respective markets; currently, it has 52 out of 59 hotels open which indicate ~80% of its total room count. Consolidated hotels occupancy increased to ~33% in March from 21% in January while nearly half of all open consolidated hotels generated positive EBITDA. Improvements led to decline in monthly burn rate to $26M in March from the average monthly burn rate of $42M during 4Q20. "Operationally, leisure demand trends continue to improve at a faster pace than we had initially anticipated, with a broader based recovery across all demand segments expected over the back half of 2021 and well into 2022," Chairman and CEO Thomas J. Baltimore, Jr. commented. / / / / / 2nd gummy- CohBar $1.25<---VAN My Cost Is Higher or right around here! CohBar initiated with a Buy at Maxim
You're gonna like my Gummy of the Day better. CVAC... Up nicely, several 1000 shares traded very early, ie like at 4AM. Always a good sign.
Park Hotels & Resorts sells W New Orleans - French Quarter for $24.1M 06:08 PK Park Hotels & Resorts announced that it has closed on the sale of the 97-room W New Orleans - French Quarter located in New Orleans, LA, for gross proceeds of approximately $24.1M, or $249,000 per key. When adjusted for Park's anticipated capital expenditures, the sale price represents a 4.3% capitalization rate on the Hotel's 2019 net operating income, or 5.8% excluding capex, or 17.9x the Hotel's 2019 EBITDA. Proceeds from the sale will be used to repay debt. Park also announced that the Company recently reopened three West Coast hotels due to improving demand trends in their respective markets. The 360-room Le Meridien San Francisco and the 171-room Hotel Adagio, Autograph Collection, both located in San Francisco, as well as the 850-room DoubleTree Hotel Seattle Airport, all reopened in late March. Park now has 52 out of 59 hotels open, accounting for nearly 80% of the Company's total room count. The Company's seven remaining suspended hotels are currently expected to reopen over the next couple of quarters as travel restrictions ease and demand recovers. The Company continues to witness encouraging improvements in demand, with occupancy at its consolidated hotels increasing from 21% in January to nearly 33% in March, while the portfolio achieved positive EBITDA in March with nearly half of all open consolidated hotels generating positive EBITDA. Hermes upgraded to Buy from Hold at Societe Generale 3rd gummy of the day- VICR-$84.80 Vicor reports Q1 EPS 34c, consensus 25c 16:14 VICR Reports Q1 revenue $88.8M, consensus $86.71M. First quarter bookings increased 41.2% to $98.9M, from $70.1M for the corresponding period a year ago, and increased sequentially 8.1% from $91.5 million for the fourth quarter of 2020. Total backlog at the end of Q1 was $157.1M, up 6.5 % from $147.6M at the end of 2020. Commenting on Q1 performance, Patrizio Vinciarelli, CEO, stated, "Q1 revenues and gross margins reflected strong demand and improved manufacturing efficiencies. Vertical integration of power packaging processes and increased capacity in expanded facilities will enable greater revenue and margin growth starting in 2022. For the balance of 2021, sequential quarterly increases in revenue are capacity constrained to 7% while bookings and backlog are expected to grow at a faster pace."
Stoney! Do you know what TLDR stands for in the vernacular of web forums? Might wanna look that one up. Hey check out OCGN. They must have had some kind of breakthrough. It took out $10. Is it the run over or will it keep going? edit: MALVERN, PA, April 21, 2021 - Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that its co-development partner, Bharat Biotech, shared positive results of the second interim analysis of its Phase 3 study of COVAXIN, a whole virion inactivated COVID-19 vaccine candidate. COVAXIN demonstrated a vaccine efficacy in mild, moderate, and severe COVID-19 disease of 78% with efficacy against severe COVID-19 disease alone of 100%. “We continue to be excited by the compelling second interim results of Bharat Biotech’s Phase 3 clinical trial. We believe that COVAXIN can help change the course of this pandemic by preventing severe COVID-19 disease including hospitalizations by 100% as well as significantly limit the spread of asymptomatic COVID-19 infections based on efficacy shown to date. We are dedicated to being a part of the solution to save lives from COVID-19 by bringing COVAXIN to the U.S. market. Based on a traditional vaccine platform that has a long-established safety profile, we believe COVAXIN is an important tool to add to our national arsenal in ending the pandemic,” said Dr. Shankar Musunuri, Chairman of the Board, Chief Executive Officer, and Co-founder of Ocugen. “The safety and efficacy demonstrated by COVAXIN is remarkable because of the prevalence of several variants of the coronavirus circulating at the time of the trial. This vaccine is based on a proven technology platform and the company plans to consider clinical development in special populations such as children,” said Dr. Bruce Forrest, member of the vaccine scientific advisory board of Ocugen. Second Interim Phase 3 Results as Reported by Bharat Biotech Bharat Biotech’s Phase 3 clinical trial enrolled 25,800 participants between 18-91 years of age in India, including 2,433 over the age of 60 and 4,500 with comorbidities. The primary endpoint of the Phase 3 clinical trial is based on the first occurrence of PCR-confirmed symptomatic (mild, moderate, or severe) COVID-19 with onset at least 14 days after the second study vaccination in serologically negative (to SARS-CoV-2) adult participants at baseline. The second interim analysis is based on accruing more than 87 symptomatic cases of COVID-19. However, due to the recent surge in cases in India, 127 symptomatic cases were recorded, resulting in a point estimate of vaccine efficacy of 78% (95%CI: 61-88) against mild, moderate, and severe COVID-19 disease. The trial will be continuing to its pre-planned conclusion. The efficacy against asymptomatic COVID-19 infection was 70%, based on a subgroup of approximately 8,000 participants who visited the clinical trial site each month for an RT-PCR test. About COVAXIN COVAXIN, India's COVID-19 vaccine by Bharat Biotech, is developed in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV). COVAXIN is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform with an excellent safety track record of more than 300 million doses supplied. In addition to generating strong immune response against multiple antigens, COVAXIN has been shown to generate memory T cell responses, for its multiple epitopes, indicating longevity and a rapid antibody response to future infections. With published data demonstrating a safety profile superior to available data for several other vaccines, COVAXIN is packaged in multi-dose vials that can be stored at 2-8⁰C. About Ocugen, Inc. Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat Biotech’s COVAXIN™ vaccine candidate for COVID-19 in the U.S. market. For more information, please visit www.ocugen.com.
Dangerous Development!!! And maybe the reason why the commercial suddenly stopped playing... They have done their job... Now they can return to their planet.- Two Senators make new push to advance self-driving cars, Reuters says 13:45 TSLA, GM, GOOGL, GOOG Two U.S. senators are working to attach legislation to allow automakers to deploy tens of thousands of self-driving vehicles on U.S. roads to a bipartisan China bill, a significant reform that could help speed the commercial use of automated vehicles, Reuters' David Shepardson reports. Senators Gary Peters, a Democrat, and John Thune, a Republican, have circulated a draft amendment seen by Reuters that would grant the U.S. National Highway Traffic Safety Administration the power to initially exempt 15,000 self-driving vehicles per manufacturer from safety standards written with human drivers in mind.
Hey it looks like Curevac isn't the only one that has a universal vaccine, if I read that OCGN 8K above right.